AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential

By Heather Cartwright

Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)

Published: 21 Mar-2015

DOI: 10.3833/pdr.v2015.i3.2099     ISSN: 1756-7874

Section: Mergers & Acquisitions



Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details